Nkarta (NKTX) Long-Term Investments (2023 - 2026)
Nkarta's quarterly Long-Term Investments came in at $33.6 million in Q1 2026, down 59.87% year-on-year from $83.7 million in Q1 2025, and up 108.41% quarter-over-quarter from $16.1 million in Q4 2025.
Nkarta has reported Long-Term Investments for 4 years, with the latest figure at $33.6 million in Q1 2026.
- For the quarter ending Q1 2026, Long-Term Investments fell 59.87% year-over-year to $33.6 million; the trailing twelve-month figure through Mar 2026 stood at $33.6 million (down 59.87% YoY), and the FY2025 full-year result was $16.1 million, down 85.41% from the prior year.
- Long-Term Investments for Q1 2026 stood at $33.6 million, up from $16.1 million in the prior quarter.
- The five-year high for Long-Term Investments was $119.5 million in Q3 2024, with the low at $6.0 million in Q1 2023.
- Average Long-Term Investments over 4 years is $51.8 million, with a median of $33.6 million recorded in 2026.
- Peak annual rise in Long-Term Investments reached 752.36% in 2025, while the deepest fall reached 85.41% in 2025.
- Tracing NKTX's Long-Term Investments over 4 years: stood at $18.7 million in 2023, then jumped by 489.45% to $110.4 million in 2024, then slumped by 85.41% to $16.1 million in 2025, then soared by 108.41% to $33.6 million in 2026.
- The last three Long-Term Investments figures came in at $33.6 million (Q1 2026), $16.1 million (Q4 2025), and $31.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 505,194.89 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.79 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 22.17 Mn |
| 10 | Nkarta | 232.80 Mn | 232.80 Mn | - | 33.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33.57 Mn |
| Dec 31, 2025 | 16.11 Mn |
| Sep 30, 2025 | 31.42 Mn |
| Jun 30, 2025 | 41.61 Mn |
| Mar 31, 2025 | 83.65 Mn |
| Dec 31, 2024 | 110.39 Mn |
| Sep 30, 2024 | 119.47 Mn |
| Jun 30, 2024 | 99.09 Mn |
| Mar 31, 2024 | 9.81 Mn |
| Jun 30, 2023 | 18.73 Mn |
| Mar 31, 2023 | 6.02 Mn |